Back to photostream

FDA to study disclosure information for accelerated approval products in oncology

FDA to study disclosure information for accelerated approval products in oncology:

The Office of Prescription Drug Promotion (OPDP) at the US Food and Drug Administration (FDA) wants to know how to better present disclosure information about products with accelerated approval to patients with cancer and their caregivers.

More info visit:bit.ly/3vksVla

 

9 views
0 faves
0 comments
Uploaded on June 18, 2021